Skip to main content
Lilly, AstraZeneca end trials of Alzheimer's drug
6/13/2018

Eli Lilly and Co. and AstraZeneca are the latest companies to abandon Alzheimer's drug trials. The companies decided to end late-stage trials for lanabecestat, a beta secretase cleaving enzyme inhibitor, after an independent data monitoring committee determined the trials were unlikely to meet their primary goals.

Full Story: